---
title: "Liquidia Reports Q2 2025 Net Loss of $41.6M, EPS of $0.49; Product Revenue Reaches $6.5M Following YUTREPIA FDA Approval"
description: "Liquidia Corporation reported a Q2 2025 net loss of $41.6 million, up from a $28.7 million loss in Q2 2024. Product revenue reached $6.5 million following FDA approval of YUTREPIA on May 23, 2025. R&D"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252651736.md"
published_at: "2025-08-12T10:31:00.000Z"
---

# Liquidia Reports Q2 2025 Net Loss of $41.6M, EPS of $0.49; Product Revenue Reaches $6.5M Following YUTREPIA FDA Approval

> Liquidia Corporation reported a Q2 2025 net loss of $41.6 million, up from a $28.7 million loss in Q2 2024. Product revenue reached $6.5 million following FDA approval of YUTREPIA on May 23, 2025. R&D expenses decreased to $6.0 million, while SG&A expenses nearly doubled to $38.8 million. Total other expenses rose to $4.1 million. Cash and cash equivalents were $173.4 million as of June 30, 2025, down from $176.5 million at the end of 2024.

Liquidia Corporation has reported its financial results for the second quarter of 2025, revealing a net loss of $41.6 million, compared to a net loss of $28.7 million for the same period in 2024. The company’s product revenue, net, amounted to $6.5 million for the three-month period ending June 30, 2025, following the full FDA approval of YUTREPIA on May 23, 2025, and the commencement of its shipment to U.S. customers in June 2025. No product revenue was recognized in the corresponding period of the previous year. Research and development expenses decreased significantly to $6.0 million, down from $9.4 million in the previous year, primarily due to reduced personnel and YUTREPIA research and development expenses. However, selling, general, and administrative expenses nearly doubled to $38.8 million, driven by increased personnel costs, legal fees related to YUTREPIA litigation, and expenses supporting its commercialization. Total other expenses increased to $4.1 million from $1.5 million in the prior year, largely due to higher borrowings under the HCR Agreement. Cash and cash equivalents stood at $173.4 million as of June 30, 2025, slightly down from $176.5 million at the end of 2024. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liquidia Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9510536-en) on August 12, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [LQDA.US - Liquidia Tech](https://longbridge.com/en/quote/LQDA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Liquidia 强调 YUTREPIA 的强劲上市表现及其增长计划 | Liquidia Technologies (LQDA) 报告了强劲的 2025 年初步业绩，YUTREPIA 在第四季度实现了估计净销售额 9010 万美元，全年销售额为 1.483 亿美元，季度环比增长 74%。该公司计划扩展销售团队， | [Link](https://longbridge.com/en/news/272071769.md) |
| Liquidia 公司首席执行官将在摩根大通医疗健康大会上发表演讲 | Liquidia Corporation 的首席执行官 Roger Jeffs 博士将于 2026 年 1 月 14 日下午 5:15（太平洋时间）在旧金山举行的第 44 届摩根大通医疗健康大会上进行演讲。公司投资者页面将提供现场直播音频网 | [Link](https://longbridge.com/en/news/271784231.md) |
| AI 需求仍强却带不动股价！英伟达四季度至今仅涨 1%，市场观望情绪转浓 | 尽管 AI 资本支出持续膨胀，英伟达股价自四季度以来仅涨约 1%。竞争格局变化成为观望情绪核心驱动：黄仁勋本月收购 Groq 技术授权印证了其他公司的竞争力；Anthropic 也转向非英伟达供应商。虽然英伟达仍为市场领导者，但垄断地位出现 | [Link](https://longbridge.com/en/news/275914142.md) |
| 富国银行仍然建议买入 Liquidia Technologies（LQDA） | Wells Fargo 分析师 Benjamin Burnett 对 Liquidia Technologies 维持买入评级，目标价为 31.00 美元。TipRanks 显示 Burnett 的平均回报为 -3.0%，成功率为 40.5 | [Link](https://longbridge.com/en/news/270188207.md) |
| Federated Hermes Inc. 购买了 Liquidia Corporation 的 320,597 股 $LQDA | 根据最近的 SEC 文件，Federated Hermes Inc.在第三季度收购了 320,597 股 Liquidia Corporation（NASDAQ:LQDA），价值约为 729 万美元。这笔交易约占 Liquidia 的 0. | [Link](https://longbridge.com/en/news/274525904.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.